Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Girotto, Gustavo
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC	Active, not recruiting	2	194	Europe, US, RoW	ISA101b, Cemiplimab, Placebo	ISA Pharmaceuticals, Regeneron Pharmaceuticals	Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive	09/24	06/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Girotto, Gustavo
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC	Active, not recruiting	2	194	Europe, US, RoW	ISA101b, Cemiplimab, Placebo	ISA Pharmaceuticals, Regeneron Pharmaceuticals	Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive	09/24	06/25